Investigation of a thrombotic tendency

Dacie and Lewis Practical Haematology

Volumn , Issue , 2006, Pages 441-463

  Laffan, Mike ^a   Manning, Richard ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70349423233     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B0-44-306660-4/50021-0     Document Type: Chapter

References (81)

1. Haemostasis, Thrombosis Task Force BCSH Investigation and management of heritable thrombophilia. British Journal of Haematology 2001, 114:512-528.
2. Greaves M Antiphospholipid antibodies and thrombosis [see comments]. Lancet 1999, 353:1348-1353.
3. Brenner B Clinical management of thrombophilia-related placental vascular complications. Blood 2004, 103:4003-4009.
4. Brandt JT, Barna LK, Triplett DA Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thrombosis and Haemostasis 1995, 74:1597-1603.
5. British Committee for Standards in Haematology Guidelines on the investigation and management of the antiphospholipid syndrome. British Journal of Haematology 2000, 109:704-715.
6. Exner T, Rickard KA, Kronenberg H A sensitive test demonstrating lupus anticoagulant and its behavioural patterns. British Journal of Haematology 1978, 40:143-151.
7. Lawrie AS, Mackie IJ, Purdy G, et al. The sensitivity and specificity of commercial reagents for the detection of lupus anticoagulant show marked differences in performance between photo-optical and mechanical coagulometers. Thrombosis and Haemostasis 1999, 81:758-762.
8. Thiagarajan P, Pengo V, Shapiro SS The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood 1986, 68:869-874.
9. Arnout J, Vanrusselt M, Huybrechts E, et al. Optimization of the dilute prothrombin time for the detection of the lupus anticoagulant by use of a recombinant tissue thromboplastin. British Journal of Haematology 1994, 87:94-99.
10. Hoagland LE, Triplett DA, Peng F, et al. APC-resistance as measured by a Textarin time assay: comparison to the APTT-based method. Thrombosis Research 1996, 83:363-373.
11. Moore GW, Smith MP, Savidge GF The Ecarin time is an improved confirmatory test for the Taipan snake venom time in warfarinized patients with lupus anticoagulants. Blood Coagulation and Fibrinolysis 2003, 14:307-312.
12. Jennings I, Kitchen S, Woods TA, et al. Potentially clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK National External Quality Assessment Scheme (NEQAS) for Blood Coagulation. Thrombosis and Haemostasis 1997, 77:934-937.
13. Triplett DA Antiphospholipid-protein antibodies: clinical use of laboratory test results (identification, predictive value, treatment). Haemostasis 1996, 26(suppl 4):358-367.
14. Kandiah DA, Krilis SA Laboratory detection of antiphospholipid antibodies. Lupus 1996, 5:160-162.
15. Wright SD, Tuddenham EG Myeloproliferative and metabolic causes. Baillieres Clinical Haematology 1994, 7:591-635.
16. Lee AY Screening for occult cancer in patients with idiopathic venous thromboembolism: no. Journal of Thrombosis and Haemostasis 2003, 1:2273-2274.
17. Piccioli A, Prandoni P Screening for occult cancer in patients with idiopathic venous thromboembolism: yes. Journal of Thrombosis and Haemostasis 2003, 1:2271-2272.
18. Lane DA, Mannucci P, Bauer K, et al. Inherited thrombophilia. I. Thrombosis and Haemostasis 1996, 76:651-662.
19. Lane DA, Mannucci P, Bauer K, et al. Inherited thrombophilia. II. Thrombosis and Haemostasis 1996, 76:824-834.
20. Tollefsen DM Laboratory diagnosis of antithrombin and heparin cofactor II deficiency. Seminars in Thrombosis and Hemostasis 1990, 16:162-168.
21. van Boven HH, Lane DA Antithrombin and its inherited deficiency states. Seminars in Hematology 1997, 34:188-204.
22. Lane DA, Olds RJ, Conard J, et al. Pleiotropic effects of antithrombin strand 1C substitution mutations. Journal of Clinical Investigation 1992, 90:2422-2433.
23. Bertina RM Specificity of protein C and protein S assays. Ricerca in Clinica E in Laboratorio 1990, 20:127-138.
24. Marlar RA, Neumann A Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. Seminars in Thrombosis and Hemostasis 1990, 16:299-309.
25. Mackie IJ, Gallimore M, Machin SJ Contact factor proteases and the complexes formed with alpha 2-macroglobulin can interfere in protein C assays by cleaving amidolytic substrates. Blood Coagulation and Fibrinolysis 1992, 3:589-595.
26. Jones DW, Mackie IJ, Winter M, et al. Detection of protein C deficiency during oral anticoagulant therapy use of the protein C:factor VII ratio. Blood Coagulation and Fibrinolysis 1991, 2:407-411.
27. Van Wijnen M, Stam JG, Chang GT, et al. Characterization of mini-protein S, a recombinant variant of protein S that lacks the sex hormone binding globulin-like domain. Biochemical Journal 1998, 330:389-396.
28. van Wijnen M, van't Veer C, Meijers JC, et al. A plasma coagulation assay for an activated protein C-independent anticoagulant activity of protein S. Thrombosis and Haemostasis 1998, 80:930-935.
29. Comp PC, Doray D, Patton D, et al. An abnormal plasma distribution of protein S occurs in functional protein S deficiency. Blood 1986, 67:504-508.
30. Aillaud MF, Pouymayou K, Brunet D, et al. New direct assay of free protein S antigen applied to diagnosis of protein S deficiency. Thrombosis and Haemostasis 1996, 75:283-285.
31. Simmonds RE, Zoller BH, Ireland H, et al. Genetic and phenotypic analysis of a large (122 member) protein S deficient kindred provides an explanation for the co-existence of type I and type III plasma phenotypes. Blood 1997, 89:4364-4370.
32. Zoller B, Garcia dFP, Dahlback B Evaluation of the relationship between protein S and C4b-binding protein isoforms in hereditary protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genetic disease. Blood 1995, 85:3524-3531.
33. Persson KE, Dahlback B, Hillarp A Diagnosing protein S deficiency: analytical considerations. Clinical Laboratory 2003, 49:103-110.
34. Lawrie AS, Lloyd ME, Mohamed F, et al. Assay of protein S in systemic lupus erythematosus. Blood Coagulation and Fibrinolysis 1995, 6:322-324.
35. D'Angelo A, Vigano D'Angelo S, Esmon CT, et al. Acquired deficiencies of protein S: protein S activity during oral anticoagulation, in liver disease, and in disseminated intravascular coagulation. Journal of Clinical Investigation 1988, 81:1445-1454.
36. Levin M, Eley BS, Louis J, et al. Postinfectious purpura fulminans caused by an autoantibody directed against protein S. Journal of Pediatrics 1995, 127:355-363.
37. Gari M, Falkon L, Urrutia T, et al. The influence of low protein S plasma levels in young women, on the definition of normal range. Thrombosis Research 1994, 73:149-152.
38. Faioni EM, Valsecchi C, Palla A, et al. Free protein S deficiency is a risk factor for venous thrombosis. Thrombosis and Haemostasis 1997, 78:1343-1346.
39. Garcia de Frutos P, Alim RI, Hardig Y, et al. Differential regulation of alpha and beta chains of C4b-binding protein during acute-phase response resulting in stable plasma levels of free anticoagulant protein S. Blood 1994, 84:815-822.
40. Dahlback B, Carlsson M, Svensson PJ Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proceedings of the National Academy of Science U.S.A. 1993, 90:1004-1008.
41. Bertina RM Laboratory diagnosis of resistance to activated protein C (APC-resistance). Thrombosis and Haemostasis 1997, 78:478-482.
42. Laffan MA, Manning R The influence of factor VIII on measurement of activated protein C resistance. Blood Coagulation & Fibrinolysis 1996, 7:761-765.
43. Koster T, Rosendaal FR, de RH, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study [see comments]. Lancet 1993, 342:1503-1506.
44. Ridker PM, Glynn RJ, Miletich JP, et al. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Annals of Internal Medicine 1997, 126:528-531.
45. de Visser MCH, Rosendaal FR, Bertina RM A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999, 93:1271-1276.
46. Poort S, Rosendaal F, Reitsma P, et al. A common genetic variation in the 3' untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996, 88:3698-3703.
47. Koster T, Blann A, Briet E, et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep vein thrombosis. Lancet 1995, 345:152-155.
48. Meijers JC, Tekelenburg WL, Bouma BN, et al. High levels of coagulation factor XI as a risk factor for venous thrombosis. New England Journal of Medicine 2000, 342:696-701.
49. O'Donnell J, Tuddenham EG, Manning R, et al. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thrombosis and Haemostasis 1997, 77:825-828.
50. Tollefsen DM Heparin cofactor II deficiency. Archives of Pathology and Laboratory Medicine 2002, 126:1394-1400.
51. Lind B, Thorsen S A novel missense mutation in the human plasmin inhibitor (alpha2-antiplasmin) gene associated with a bleeding tendency. British Journal of Haematology 1999, 107:317-322.
52. Fay WP, Parker AC, Condrey LR, et al. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood 1997, 90:204-208.
53. Lane D, Grant P Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000, 95:1517-1532.
54. Crowther MA, Roberts J, Roberts R, et al. Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. Thrombosis and Haemostasis 2001, 85:390-394.
55. Thompson SG, Kienast J, Pyke SD, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. New England Journal of Medicine 1995, 332:635-641.
56. Pyke SD, Thompson SG, Buchwalsky R, et al. Variability over time of haemostatic and other cardiovascular risk factors in patients suffering from angina pectoris. ECAT Angina Pectoris Study Group. Thrombosis and Haemostasis 1993, 70:743-746.
57. Juhan VI, Pyke SD, Alessi MC, et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996, 94:2057-2063.
58. Ridker PM, Vaughan DE, Stampfer MJ, et al. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993, 341:1165-1168.
59. Kluft C, Meijer P Update 1996: Blood collection and handling procedures for assessment of plasminogen activators and inhibitors (Leiden fibrinolysis workshop). Fibrinolysis 1996, 10:171-179.
60. Dolan G, Greaves M, Cooper P, et al. Thrombovascular disease and familial plasminogen deficiency: a report of three kindreds. British Journal of Haematology 1988, 70:417-421.
61. Heijboer H, Brandjes DP, Buller HR, et al. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis [see comments]. New England Journal of Medicine 1990, 323:1512-1516.
62. Wiman B, Chmielewska J A novel fast inhibitor to tissue plasminogen activator in plasma, which may be of great pathophysiological significance. Scandinavian Journal of Clinical Laboratory Investigation Suppl 1985, 177:43-47.
63. Nilsson IM, Ljungner H, Tengborn L Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. British Medical Journal Clinical Research and Education 1985, 290:1453-1456.
64. Marsh NA, Gaffney PJ The rapid fibrin plate: a method for plasminogen activator assay. Thrombosis and Haemostasis 1977, 38:545-551.
65. Juhan VI, Valadier J, Alessi MC, et al. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thrombosis and Haemostasis 1987, 57:67-72.
66. Wieczorek I, Ludlam CA, MacGregor I Venous occlusion does not release von Willebrand factor, factor VIII or PAI-1 from endothelial cells: the importance of consensus on the use of correction factors for haemoconcentration [letter] [see comments]. Thrombosis and Haemostasis 1993, 69:91. 93.
67. Marckmann P, Sandstrom B, Jespersen J The variability of and associations between measures of blood coagulation, fibrinolysis and blood lipids. Atherosclerosis 1992, 96:235-244.
68. Stegnar M, Mavri A Reproducibility of fibrinolytic response to venous occlusion in healthy subjects. Thrombosis and Haemostasis 1995, 73:453-457.
69. Mahmoud M, Gaffney PJ Bioimmunoassay (BIA) of tissue plasminogen activator (t-PA) and its specific inhibitor (t-PA/INH). Thrombosis and Haemostasis 1985, 53:356-359.
70. Holvoet P, Cleemput H, Collen D Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thrombosis and Haemostasis 1985, 54:684-687.
71. Collen D The plasminogen (fibrinolytic) system. Thrombosis and Haemostasis 1999, 82:259-270.
72. Wu KK, Hoak JC Spontaneous platelet aggregation in arterial insufficiency: mechanisms and implications. Thrombosis and Haemostasis 1976, 35:702-711.
73. Lozano ML, Gonzalez-Conejero R, Corral J, et al. Polymorphisms of P-selectin glycoprotein ligand-1 are associated with neutrophil-platelet adhesion and with ischaemic cerebrovascular disease. British Journal of Haematology 2001, 115:969-976.
74. Theodoropoulos I, Christopoulos C, Metcalfe P, et al. The effect of human platelet alloantigen polymorphisms on the in vitro responsiveness to adrenaline and collagen. British Journal of Haematology 2001, 114:387-393.
75. Bennett JS, Catella-Lawson F, Rut AR, et al. Effect of the Pl(A2) alloantigen on the function of beta(3)-integrins in platelets. Blood 2001, 97:3093-3099.
76. Afshar-Kharghan V, Li CQ, Khoshnevis-Asl M, et al. Kozak sequence polymorphism of the glycoprotein (GP) Ib alpha gene is a major determinant of the plasma membrane levels of the platelet GP Ib-IX-V complex [see comment]. Blood 1999, 94:186-191.
77. Abrams CS, Ellison N, Budzynski AZ, et al. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1990, 75:128-138.
78. Michelson AD Flow cytometry: a clinical test of platelet function. Blood 1996, 87:4925-4936.
79. D'Angelo A, Selhub J Homocysteine and thrombotic disease. Blood 1997, 90:1-11.
80. Bauer KA, Rosenberg RD Activation markers of coagulation. Baillieres Clinical Haematology 1994, 7:523-540.
81. Morrissey JH, Macik BG, Neuenschwander PF, et al. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993, 81:734-744.